Skip to content
2000
Volume 14, Issue 5
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

Background: Group A streptococcus (GAS) primarily colonizes the mucosal region of the upper respiratory tract, slowly leading to systemic infections. Thus, GAS-specific antibody responses are desirable at mucosal sites for early prevention against GAS colonization. Methods: Herein, we developed a potent nanoliposomes-based delivery system for mucosally active lipid core peptide (LCP)-based vaccines. Results: Trimethyl chitosan (TMC)-coated liposomes that bore a B-cell epitope derived from GAS Mprotein, stimulated potent epitope-specific mucosal and systemic antibody titres after only one boost following intranasal immunization in Swiss outbred mice. The immune responses were durable even at day 139 post-primary immunization. Conclusion: The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process of producing the coated nanoliposomes should be particularly useful in developing potent peptide-based vaccines to prevent infections at the mucosal sites.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/1567201813666160721141322
2017-08-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/1567201813666160721141322
Loading

  • Article Type:
    Research Article
Keyword(s): Chitosan; group A streptococcus; lipopeptides; liposomes; nasal delivery; peptide vaccines
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test